Cargando…

Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin

BACKGROUND: Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis. METHODS: The relationship of AC subtype and expressio...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhao, Xiang-qian, Dong, Jia-hong, Zhang, Wen-zhi, Liu, Zhe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213044/
https://www.ncbi.nlm.nih.gov/pubmed/21992455
http://dx.doi.org/10.1186/1746-1596-6-98
_version_ 1782216067567845376
author Zhao, Xiang-qian
Dong, Jia-hong
Zhang, Wen-zhi
Liu, Zhe
author_facet Zhao, Xiang-qian
Dong, Jia-hong
Zhang, Wen-zhi
Liu, Zhe
author_sort Zhao, Xiang-qian
collection PubMed
description BACKGROUND: Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis. METHODS: The relationship of AC subtype and expression of Osteopontin (OPN) with the prognosis of 120 AC patients after pancreaticoduodenectomy was investigated. RESULTS: The patients had pancreatobiliary (CK7(+)/CK20(-), n = 24, 20%), intestinal (CK7(-)/CK20(+), n = 29, 24.2%) or other (CK7(+)/CK20(+ )or CK7(-)/CK20(-), n = 67, 55.8%) subtypes of AC, and their median survival times were 23 ± 4.2, 38 ± 2.8 and 64 ± 16.8 months, respectively. The survival times of 64 OPN(- )patients (53.3%) and 56 OPN(+ )patients (46.7%) were 69 ± 18.4 and 36 ± 1.3 months, respectively. There was no significant effect of AC subtype on survival of OPN(- )patients. For OPN(+ )patients, those with pancreatobiliary AC had a shorter survival time (22 ± 6.6 months) than those with intestinal AC (37 ± 1.4 months, p = 0.041), and other AC subtype (36 ± 0.9 months, p = 0.010); intestinal and other AC subtypes had similar survival times. CONCLUSIONS: The prognosis of AC patients can be estimated based on immunohistochemical classification and OPN status.
format Online
Article
Text
id pubmed-3213044
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-32130442011-11-11 Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin Zhao, Xiang-qian Dong, Jia-hong Zhang, Wen-zhi Liu, Zhe Diagn Pathol Research BACKGROUND: Ampullary cancer (AC) was classified as pancreatobiliary, intestinal, or other subtype based on the expression of cytokeratin 7 (CK7) and cytokeratin 20 (CK20). We aimed to explore the association of AC subtype with patient prognosis. METHODS: The relationship of AC subtype and expression of Osteopontin (OPN) with the prognosis of 120 AC patients after pancreaticoduodenectomy was investigated. RESULTS: The patients had pancreatobiliary (CK7(+)/CK20(-), n = 24, 20%), intestinal (CK7(-)/CK20(+), n = 29, 24.2%) or other (CK7(+)/CK20(+ )or CK7(-)/CK20(-), n = 67, 55.8%) subtypes of AC, and their median survival times were 23 ± 4.2, 38 ± 2.8 and 64 ± 16.8 months, respectively. The survival times of 64 OPN(- )patients (53.3%) and 56 OPN(+ )patients (46.7%) were 69 ± 18.4 and 36 ± 1.3 months, respectively. There was no significant effect of AC subtype on survival of OPN(- )patients. For OPN(+ )patients, those with pancreatobiliary AC had a shorter survival time (22 ± 6.6 months) than those with intestinal AC (37 ± 1.4 months, p = 0.041), and other AC subtype (36 ± 0.9 months, p = 0.010); intestinal and other AC subtypes had similar survival times. CONCLUSIONS: The prognosis of AC patients can be estimated based on immunohistochemical classification and OPN status. BioMed Central 2011-10-13 /pmc/articles/PMC3213044/ /pubmed/21992455 http://dx.doi.org/10.1186/1746-1596-6-98 Text en Copyright ©2011 Zhao et al; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research
Zhao, Xiang-qian
Dong, Jia-hong
Zhang, Wen-zhi
Liu, Zhe
Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin
title Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin
title_full Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin
title_fullStr Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin
title_full_unstemmed Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin
title_short Prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin
title_sort prognosis of ampullary cancer based on immunohistochemical type and expression of osteopontin
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3213044/
https://www.ncbi.nlm.nih.gov/pubmed/21992455
http://dx.doi.org/10.1186/1746-1596-6-98
work_keys_str_mv AT zhaoxiangqian prognosisofampullarycancerbasedonimmunohistochemicaltypeandexpressionofosteopontin
AT dongjiahong prognosisofampullarycancerbasedonimmunohistochemicaltypeandexpressionofosteopontin
AT zhangwenzhi prognosisofampullarycancerbasedonimmunohistochemicaltypeandexpressionofosteopontin
AT liuzhe prognosisofampullarycancerbasedonimmunohistochemicaltypeandexpressionofosteopontin